Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Front Immunol. 2023 Aug 28;14:1237978. doi: 10.3389/fimmu.2023.1237978. eCollection 2023.
Cancer is one of the leading causes of death worldwide. The burden of cancer on public health is becoming more widely acknowledged. Lung cancer has one of the highest incidence and mortality rates of all cancers. The prevalence of early screening, the emergence of targeted therapy, and the development of immunotherapy have all significantly improved the overall prognosis of lung cancer patients. The current state of affairs, however, is not encouraging, and there are issues like poor treatment outcomes for some patients and extremely poor prognoses for those with advanced lung cancer. Because of their potent immunomodulatory capabilities, thymosin drugs are frequently used in the treatment of tumors. The effectiveness of thymosin drugs in the treatment of lung cancer has been demonstrated in numerous studies, which amply demonstrates the potential and future of thymosin drugs for the treatment of lung cancer. The clinical research on thymosin peptide drugs in lung cancer and the basic research on the mechanism of thymosin drugs in anti-lung cancer are both systematically summarized and analyzed in this paper, along with future research directions.
癌症是全球主要死因之一。癌症对公共卫生的负担越来越受到广泛认识。肺癌是所有癌症中发病率和死亡率最高的癌症之一。早期筛查的普及、靶向治疗的出现以及免疫疗法的发展都显著改善了肺癌患者的总体预后。然而，现状并不乐观，一些患者的治疗效果不佳，晚期肺癌患者的预后极差。胸腺肽类药物因其强大的免疫调节能力，常被用于肿瘤的治疗。大量研究表明，胸腺肽类药物在肺癌治疗中的有效性，充分证明了胸腺肽类药物在肺癌治疗中的潜力和未来。本文系统总结和分析了胸腺肽类药物在肺癌中的临床研究和胸腺肽类药物抗肺癌作用机制的基础研究，并提出了未来的研究方向。
